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Background: The introduction of antiretroviral therapy (ART) has dramatically reduced the mortality rate of people
living with HIV (PLHIV). However, complications of both HIV and ART, such as peripheral neuropathy currently affect
PLHIV. The purpose of this study was to establish the prevalence of peripheral neuropathy of the lower extremity
and, its association with demographic and health status, characteristics among people on ART in Rwanda.
Methods: A cross sectional study was conducted among 507 women and men aged between 18 and 60 years, on
ART, randomly selected from eight selected ART clinics in Rwanda. Brief Peripheral Neuropathy Screen was used to
assess peripheral neuropathy.
Results: Peripheral neuropathy prevalence was 59% overall, mean age of the participants was 39.7 (±9.2) and a
slightly older age was associated with peripheral neuropathy; [42(±9.2) vs 37 (±8.8) (p < 0.001)]. 78% of participants
living in urban settings compared to 40% in rural settings reported peripheral neuropathy, 69% of participants with
higher levels of education (secondary level and above) reported lower extremity neuropathy.
The three factors were significantly associated with peripheral neuropathy in multivariable model analysis: older age
[aOR = 1.1, 95% CI (1.0, 1.2), p < 0.001], primary education level [aOR = 0.6 95% Cl (0.3, 1.0), p = 0.04] and urban setting
[aOR = 0.1, 95% CI (0.06, 0.3), p < 0.001], after adjusting for other factors. None of the health status characteristics
namely; the level of CD4 cell count, duration of HIV infection and duration on ART, was independently associated with
peripheral neuropathy.
Conclusions: The prevalence of peripheral neuropathy among PLHIV on ART in Rwanda is high. It is unclear why
urban setting has an effect on PN levels in this cross sectional study, but does suggest that unidentified social and
lifestyles factors may have a role in subjective symptoms and objective signs, of PN.
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HIV/AIDS continues to cause high mortality and mor-
bidity in many sub – Saharan African countries [1]. The
introduction of antiretroviral combination therapy has
dramatically reduced the mortality rate of people living
with HIV [2,3]. However, with substantially expanded life
expectancy and the long-term use of antiretroviral* Correspondence: dtumusime@khi.ac.rw
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unless otherwise stated.therapy, complications such as peripheral neuropathy
(PN) are the most prevalent neurological manifestations
now seen in HIV/AIDS [4]. Peripheral neuropathy com-
monly affects people’s daily function and quality of life
(QoL) among populations with HIV infection [5]. In
addition, the PN is likely enhanced by various demo-
graphic and health status characteristics, among the
PLHIV [6]. Existing data on prevalence of peripheral
neuropathy is poor and there is no known data as to
how peripheral neuropathy is associated with different
demographic and health status characteristics of PLHIVtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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care intervention such as physiotherapy. The purpose of
this study was to establish the prevalence of PN of the
lower extremity, and the associated demographic and
health status characteristics, among PLHIV on ART in
Rwanda.
Methods
Study design, participants and setting
A cross sectional study was conducted among adult men
and women participants aged 18 and above, with HIV infec-
tion and on ART. In Rwanda since 2011, all people with
HIV and who have less than 350 m//m3 of CD4 cell counts,
are put on ART. The first line regimen contains Tenofovir +
Emtricitabine/Lamivudine + Nevirapine/Efavirenz or
Abacavir + Lamivudine +Nevirapine/Efavirenz (TDF+FTC/
3TC + NVP/EFV or ABC + 3TC +NVP/EFV). However,
a few cases might still take d4T in the first line depend-
ing on the health status of the patient [7].
Clinical information from the patients’ medical files,
about the pathologies which might be associated with
peripheral neuropathy, was assessed. From the informa-
tion, the participants with known active opportunistic
infection such as TB or others, disorders of the central
nervous system, history of diabetes, Vitamin B12 defi-
ciency, renal failure, hypothyroidism and other pathologies,
were excluded from the study sample. The participants
were identified from eight randomly selected public ART
clinics from all four provinces and the city of Kigali, in
Rwanda. Participants attended the clinics for routine health
care management that included; receiving ARV medica-
tion, health care consultations, counselling and other ad-
vice, and laboratory testing including CD4 cell count
monitoring. A systematic random sampling was used to in-
vite volunteers for participation. The pilot study [7] prior
to this study indicated that this sampling procedure was
feasible and practical. Therefore, a list of potential partici-
pants was made at every visit at each selected clinic and
the process was repeated each day for a period of two
weeks. The total number of potential participants (N) on
the list made for each visit was multiplied by 20% to
get the sample (n) of participants on each visit/day
(n = N*20%). The study population was considered as a
homogeneous population, thus the systematic random se-
lection was done by randomly choosing the first person
between 1 and K, then taking every Kth number thereafter,
where Kth was a sampling interval on the ordered list
made for a day. The Kth was calculated by dividing the
total number of the participants on the list (N), by the
sample size to be selected per day (n); (Kth = N/n), [8].
The procedure was repeated for a period of two weeks
(10 working days) which was the maximum period des-
ignated for data collection at each selected ART clinic.
A total number of 3180 PLHIV were registered to haveattended the eight selected ART clinic services within
the two week period of the study. Using the procedure
described above, a sample of 636 potential participants
was systematically and randomly invited from the total
registered number (3180). The whole process of data col-
lection at the eight selected ART clinics took 16 weeks
(two weeks at each clinic) from March to July 2012.
An ethical clearance certificate (protocol number
M080812) was obtained from the Human Research Ethics
Committee at the University of the Witwatersrand. As the
data were collected in Rwanda, national ethical clear-
ance (No. 032IRB052011) was also obtained from the
Institutional Review Board at Kigali Health Institute and
the proposal was scientifically approved by the National
Commission for Control of HIV and AIDS (approval
letter No. 0137/CNLS/2011/S.E), in Rwanda. An infor-
mation letter explaining the details of the study and
inviting participants to participate in it was given to
them prior to their recruitment into the study. Partici-
pants signed a consent form agreeing to their participa-
tion and giving their permission to use their medical
records/files.
Recording of demographic and health status,
characteristics
The demographics captured included age, gender, level
of education, marital status, and place of residence,
namely; a rural or urban setting. Health status informa-
tion included the duration of HIV infection, current
ARV regimen combination, duration on ART, other
pathologies (the ones listed in the exclusion criteria
above) that could cause PN, the most recent CD4 cell
count level, and whether the participant presented PN
symptoms (PNS) prior to starting on ART or afterwards.
We gathered the information from the participants
themselves and from their medical file records. The
medical file records considered were on papers (hard
copies) and those with missing needed data were ex-
cluded. About 21 file records had some missing data and
these were replaced with additional file of the partici-
pants (after screening them for inclusion criteria) with
complete records to avoid reduced sample size for the
power calculation. The checklist was completed by trained
staff together with the participant, and assistance was
sought when needed from the medical practitioner work-
ing at the respective outpatient ART clinic.
Assessment of peripheral neuropathy
A brief peripheral neuropathy screen (BPNS), which is a
validated tool to assess HIV – associated peripheral
neuropathy [9] was used to assess the PN in Rwanda in
a prior study [10], and thus was again used to assess PN
in this study. The BPNS assesses subjective symptoms
and objective signs, of PN. Three assessors; DT, JT and
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using the guidelines and principles described in other
studies [5]. All the assessors were blinded to any clinical
symptoms and signs of the participant, before start on
ART. The assessment included; asking participants to
rate the presence and severity of symptoms for each leg
separately, using a scale of 1 (mild) to 10 (severe). Symp-
toms included pain, aching, or burning in feet and/or
legs, pins and needles in feet and/or legs and numbness
in feet and/or legs. The single highest of the six scores
(three for each leg) was then converted to a subjective
peripheral neuropathy grade as follows: symptoms
absent = grade 0, score 1–3 = grade 1, score of 4–6 =
grade 2, and score of 7–10 = grade 3. Symptoms did not
have to be bilateral to be graded as ≥ 1. Objective find-
ings included in the BPNS were loss of vibration percep-
tion and abnormal ankle deep tendon reflexes. Vibration
perception was evaluated using a 128-Hz tuning fork,
maximally struck and applied to the distal interphalan-
geal joint of the hallux of each foot. Vibration sense was
defined as normal for a vibration felt for > 10 seconds,
mild loss for 6–10 seconds, moderate loss for ≥ 5 sec-
onds, and severe loss for no feeling of vibration. Ankle
reflexes were defined as absent, hypoactive, normal,
hyperactive, or clonus. The primary outcome of interest
in this measure was the presence of PN, which was de-
fined as the combination of at least one subjective
neuropathy grade greater than 0 and either abnormal
vibratory sense or ankle deep tendon reflex, bilaterally,
as has been defined and used in previous studies [5,9].
Statistical analysis
Descriptive analysis; tabulations for frequencies and
percentages for categorical variables and measures of
central tendency (means) and measures of variability
(standard deviations) for continuous variables, were
used. A bivariate analysis using Pearson’s Chi – square
or appropriate Fisher’s exact tests was used when ana-
lysing the prevalence distribution of PN and its associ-
ation with categorical demographic and health status
variables. The demographic variables included gender,
level of education, occupation, marital status and place
of residence. Health status variables included the dur-
ation of HIV infection, current ARV regimen combin-
ation, duration on ART, the most current CD4 count
and presence of PN symptoms and onset date of PN
symptoms. The student’s t-test (or Mann Whitney for
non-normally distributed data) was used for pairs of
continuous variables.
Variables which were statistically significant in a uni-
variate model were further included into the multivariate
model with logistic regression analysis, to establish the
association of PN and its magnitude (odds ratio), upon
controlling of confounding factors. The analysis wasdone using STATA (version 11, Stata Corp, College
Station, Texas, USA) and the level of significance was
set at 5%, hence statistical significance was achieved
when p < 0.05.
Results
Participants and prevalence of peripheral neuropathy
With the sample of six hundred and thirty six (636) po-
tential participants randomly invited to participate in the
study, five hundred and seven (507), equivalent to 80%
of the sample were eligible according to the set inclusion
criteria mentioned in the method section. The partici-
pants completed the outcome measures and their data
were eligible for analysis. Out of the analysed sample of
507, three hundred (300/507) equivalent to 59% [95% CI
(54%, 63%)] were diagnosed with PN using the BPNS.
Peripheral neuropathy and demographic characteristics
The distribution and association of PN with the demo-
graphic characteristics is shown in Table 1 with the
mean age of the participants being 39.7 (SD ±9.2). Par-
ticipants with PN were slightly older than those without
PN [42(SD ± 9.2) vs 37 (±8.8) (p < 0.001)]. PN was more
predominant (69%) among participants with a higher
level of education (p < 0.01). With the chi-square for
categorical variables, there was a statistically signifi-
cance (p < 0.001) difference in distribution of PN among
the participants across the occupational activities. The dif-
ference in distribution of PN with marital status was sig-
nificant (p = 0.003) also. Peripheral neuropathy among
participants living in the urban setting was 78% compared
to 40% among the ones living in the rural setting (p < 0.01).
Peripheral neuropathy and health status characteristics
Table 2 shows that there was no significant difference
(p = 0.98) in distribution of PN among participants with
different CD4 cell count levels. A statistically significant
difference (p = 0.002) was found in the distribution of
PN among participants with different durations of HIV
infection. PN appeared in 73% of participants who had
the infection for the last seven and above years. Simi-
larly, a longer duration on ARVs was associated with
PN (p = 0.001), which was predominantly observed in
the period of 4 – 6 years, but with almost 10% less
among those of 7 years and above. Table 3 reveals that
almost all PN characteristics were significantly associ-
ated (p < 0.001) with the participants’ settings, where
the PN appeared more severe among the urban
dwellers.
The demographic and health status characteristics
predicting the prevalence of Peripheral Neuropathy
Univariate analysis in Table 4, demonstrates that PN is
associated with demographic characteristics such as age
Table 1 Distribution of PN and its association with demographic characteristics
PN n (%) n = 507
Variable No PN (n = 207) PN (n = 300) p-value All
Age (mean ± SD) 37 (±8.8) 42 (±9.2) <0.001 39.8 (±9.2)
Gender Female 156 (43) 210 (57) 0.402 366 (73)
Male 51 (37) 87 (63) 138 (27)
Education None 39 (35) 73 (65) 0.002* 112 (22)
Primary 123 (49) 128 (51) 251 (50)
> = Secondary 45 (31) 99 (69) 144 (28)
Occupation Public employed 13 (31) 29 (69) <0.001* 42 (8)
Peasant/Farmer 118 (53) 106 (47) 224 (44)
Self employed 33 (37) 56 (63) 89 (18)
Unemployed 43 (28) 109 (72) 152 (30)
Marital status Single 17 (49) 18 (51) 0.003* 35 (7)
Married 119 (52) 112 (48) 231 (46)
Divorced/Separated 18 (22) 63 (78) 81 (16)
Window/Widower 53 (33) 107 (67) 160 (31)
Setting/Residence Urban 58 (22) 200 (78) <0.001* 258 (51)
Rural 149 (60) 99 (40) 248 (49)
*Denotes significant association, SD = Standard deviation, n = number of participants.
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[OR = 0.6, 95% Cl (0.4, 0.9) p < 0.01], occupation (being
peasant or a farmer compared to public employed) [OR =
0.4, 95% CI (0.2, 0.8) (p < 0.01], marital status [OR = 3.3,
95% CI (1.0, 4.0) p < 0.01] and with rural versus urban set-
ting [OR = 0.2, 95% CI (0.1, 0.3) p < 0.001]. Health statusTable 2 Distribution of PN and its association with health sta
Variable
CD4 cell count <=350
>350
Duration since HIV diagnosis 0 – 3 years ago
4 – 6 years ago
7 and above yrs
Current ARV regimen Non d4T containing
d4T containing




ARV regimen changes None
Once
Two and more
ARV started with Non D4T containing
D4T containing
*Denotes significant association, n = number of participants.characteristics predicting PN include duration of HIV
infection [OR = 2.3, 95% CI (1.5, 3.7) p = 0.001], and the
duration on ART [OR = 2.4; 95% CI (1.5, 3.8) (p < 0.001)],
95% CI (1.5, 3.9); (p < 0.001)] and ≥ 7 years [OR = 3.1; 95%
CI (1.6, 6.1). All significantly associated characteristics
with PN in the univariate analysis were put into thetus characteristics of the participants
PN n (%) n = 507
No PN PN p-value All
63 (51) 91 (49) 0.98 154 (30)
144 (41) 209 (59) 353 (70)
72 (46) 84 (54) <0.001* 156 (31)
91 (49) 96 (51) 187 (37)
44 (27) 120 (73) 164 (32)
156 (39) 247 (61) 0.056 403 (79)
51 (49) 53 (51) 104 (21)
71 (58) 52 (42) <0.001* 123 (24)
58 (36) 101 (64) 159 (32)
61 (30) 108 (64) 169 (33)
17 (41) 39 (70) 56 (11)
44 (43) 48 (57) 0.045 102 (20)
120 (44) 150 (56) 270 (53)
43 (32) 92 (68) 135 (27)
62 (37) 104 (63) 0.27 166 (33)
145 (43) 196 (57) 341 (67)
Table 3 Prevalence of PN characteristics among the
participants in urban and rural settings
PN characteristic measures Settings n (%)
n = 507
Urban Rural p-value
PN in the feet Absent 81 (33) 129 (52) <0.001*
Present 167 (67) 119 (48)
PNS severity None 31 (13) 130 (52) <0.001*
Mild 48 (20) 27 (11)
Moderate 78 (32) 40 (16)
Severe 88 (36) 47 (19)
PNS distribution None 34 (13) 134 (54) <0.001*
Feet only 74 (29) 46 (20)
Ankle to knee 95 (37) 66 (29)
Above knee 55 (21) 48 (21)
Sense of vibration Reduced/absent 213 (83) 98 (40) <0.001*
Normal 45 (17) 150 (60)
Ankle reflex Reduced/absent 190 (74) 94 (38) <0.001*
Normal 68 (26) 154 (62)
*Denotes significant p-value for the association.
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vealed that some characteristics were independently asso-
ciated with the PN. These include age [aOR = 1.06, 95%
CI (1.03, 1.08) p < 0.001], level of education [aOR = 0.6,
95% Cl (0.3, 1.0) p = 0.04], some categories of the duration
on ART [1-3 years = aOR: 2.6, Cl (1.4, 4.8) p < 0.001, 4-7
years = aOR: 2, Cl (1.0, 4.1) p < 0.05] and urban versus
rural setting [aOR = 0.1, 95% CI (0.06, 0.3) p < 0.001].
Thus, age, level of education, duration on ART and the
urban versus rural setting were the major predictors of
PN in this study.Discussion
HIV has changed from being a terminal illness to a
chronic condition in the ART era [11] and PLHIV are
now living longer. However, living with HIV and on
ART has complications that include PN which are disab-
ling [12]. Peripheral neuropathy has been reported as
one of the common neurological complications of HIV
infection in the ART era [4,13]. HIV – associated neur-
opathy is reported as a cause of morbidity among PLHIV
due to the effects on their quality of life [13,14]. This
study identified the prevalence of PN and its association
with demographic and health status, characteristics of
PLHIV on ART from selected rural and urban ART
clinics in Rwanda.
The overall prevalence of PN was very high (59%) in
this study compared to previous studies conducted in
Rwanda. However, the prevalence of 40% demonstrated
in this study in rural dwellers is the same as the previousstudy in Rwanda [15] that found a prevalence of 40.5%
from one rural district hospital. But, the previous study
was conducted in only one rural district hospital and
had a smaller sample size, compared to our study that
covered four selected rural health facilities. Overall, our
study was conducted in eight health facilities selected
from both rural and urban settings and with increased
sample size. Secondly, our study used a more rigorous
assessment instrument for the PN; the BPNS. The previ-
ous study [15] used the Subjective Peripheral Neuropathy
Screen (SPNS) that evaluates peripheral neuropathy symp-
toms (PNS) subjectively [16], unlike the BPNS that
evaluates signs objectively in addition to the subjective
assessment. The objective evaluation such as the deep
tendon reflex and sense of vibration may detect neuro-
logical signs in asymptomatic participants [5]. The
SPNS is unlikely to detect all patients with PN and will
underestimate the prevalence of PN, as Evans et al., [6]
reported that PN may frequently occur without symp-
toms, and PN may vary depending on the defined cri-
teria used [12].
The prevalence in our study is higher than in most
other studies in Africa, such as by Luma et al., [14] in
Cameroon with 28%, and Mehta et al., [5] in Kenya with
36%. The prevalence of PN in our study is slightly lower
than one in Brazil by Zanetti et al., [17] where the preva-
lence was 69.4%. Some factors that may explain the dif-
ferences between our study and the one in Brazil [17],
include the population’s average age, types of medica-
tions (ART regimen), diseases (HIV) stage, procedures
to control PN, unidentified environmental factors and
sample size, could all contribute to the findings of differ-
ing prevalence rates.
An older age was associated with the PN. This is simi-
lar to other studies in which age has been identified as a
risk factor for developing PN [5,6,12,18,19]. Monitoring
PN occurrence is important for possible and appropriate
management in this group. The study by Haanpää and
colleagues, [20] highlighted that early identification and
management of the neuropathic pain symptoms is im-
portant in primary care to improve the quality of life.
This study indicated a higher prevalence of PN in
people on ART living in urban than in rural settings in
Rwanda. The very big difference between rural and
urban rates is puzzling. A possible reason for the differ-
ence may be that people living in a Rwandan urban set-
ting are more likely to be physically inactive [21].
Physical inactivity has been reported as a risk factor for
neuromuscular conditions (which may include PN) in
PLHIV [22]. Similarly, increased body weight is usually
common among people who are physically inactive. This
has been identified in one of the studies conducted in
Rwanda as a risk factor for neuropathy, although we
did not measure it [23]. Again, the literature shows that
Table 4 Univariate and multivariate analysis for the associated and predicting demographic and health status
characteristics, to PN
Characteristics Prevalence (%)
of PN (n = 300)
Univariate models Multivariate models
Odds ratio (OR)
(95% CI)
p-value Adjusted odds ratio
(aOR) (95% CI)
p-value
Age 42 (±9.2) 1.1 (1.0, 1.1) <0.001 1.1 (1.0, 1.1) <0.001*
Gender Female 210 (57) 1.0 (ref) 0.25
Male 87 (63) 1.3 (0.8, 1.9)
Education None 73 (65) 1.0 (ref) 1.0 (ref)
Primary 128 (51) 0.6 (0.4, 0.9) 0.01 0.6 (0.3, 1.0) 0.04*
> = Secondary 99 (69) 1.2 (0.7, 2.0) 0.55 0.6 (0.3, 1.3) 0.2
Occupation Public employed 29 (69) 1.0 (ref) 1.0 (ref)
Peasant/Farmer 106 (47) 0.4 (0.2, 0.8) 0.01 0.9 (0.3, 2.2) 0.76
Self employed 56 (63) 0.8 (0.3, 1.7) 0.5 0.3 (0.1, 0.9) 0.03
Unemployed 109 (72) 1.1 (0.5, 2.4) 0.74 0.6 (0.2, 1.4) 0.22
Marital status Single 18 (51) 1.0 (ref)
Married 112 (48) 0.9 (0.4, 1.8) 0.75
Divorced/Separated 63 (78) 3.3 (1., 4) <0.01
Window/Widower 107 (66) 1. 9 (0.9, 4.) 0.09
Setting/Residence Urban 200 (78) 1.0 (ref) 1.0 (ref)
Rural 99 (40) 0.2 (0.1, 0.3) <0.001 0.1 (0.06, 0.3) <0.001*
CD4 cell count <=350 91 (49) 1.0 (ref)
>350 209 (59) 1.0 (0.7, 1.5) 1.008
Duration since HIV diagnosis 0 – 3 years ago 84 (54) 1.0 (ref) 1.0 (ref)
4 – 6 years ago 96 (51) 0.9 (0.6, 1.4) 0.60 0.6 (0.3,1.1) 0.08
7 and above yrs 120 (73) 2.3 (1.5, 3.7) <0.001 1.4 (0.7, 3.0) 0.33
Current ARV regimen Non D4T containing 247 (61) 1.0 (ref)
D4T containing 53 (51) 1.0 (0.4, 1.0) 0.06
Duration on ARVs (in years) 0 – 1 52 (42) 1.0 (ref) 1.0 (ref)
1 – 3 101 (64) 2.4 (1.5, 3.8) <0.001 2.6 (1.4, 4.8) 0.001
4 – 6 108 (64) 2.4 (1.5, 3.9) <0.001 2.0 (10, 4.1) 0.05
7 and above 39 (70) 3.1 (1.6, 6.1) 0.001 2.2 (0.8, 5.9) 0.1
ARV regimen changes None 48 (57) 1.0 (ref)
Once 150 (56) 0.9 (0.6, 1.5) 0.80
Two and more 92 (68) 1.6 (1.0, 2.8) 0.08
ARV started with Non D4T containing 104 (63) 1.0 (ref)
D4T containing 196 (57) 0.8 (0.6, 1.2) 0.27
*Denotes significant p-value for the association of the characteristics with PN in a multivariate model, CI = Confidence Interval.
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morbidities [24] such as lipodystrophy which is a potential
mediator for PN in HIV [25]. Although this study did not
assess weight and lipodystrophy, Mutimura et al., [26] in-
dicated that lipodystrophy was more prevalent among
PLHIV in urban than rural, settings in Rwanda. Routine
monitoring and assessment of PN, physical inactivity, and
body weight particularly in urban settings, would be useful
to develop appropriate strategies for the management of
PN among PLHIV.The CD4 cell count was not associated with PN, con-
trary to what has been found in other studies done in
Africa, such as the study by [27] in Burkina Faso, and
the study by Luma et al. [14] in Cameroon. Our study
was cross sectional and all participants were outpatients
and most of them (70%) had CD4 count of 350 m//m3
and above. This might explain the differences as de-
creased CD4 cell count has been shown to be associ-
ated with co-morbidities including PN in PLHIV [28].
Similar findings of non associated decreased CD4 cell
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Morgello et al., [29] and a study by Schifitto with col-
leagues [30]. This implies CD4 might not be a measure
of risks once on ART [11].
Likewise, the d4T containing regimen was not associ-
ated with PN, which is contrary to the findings in other
studies [27,31,32], however, is similar with the study by
Luma et al. [14] which showed no association of d4T
use with PN. A possible reason being that people who
experience PN as result of d4T have it in the initial
stages of the therapy [33,34]. In their study, Hung and
colleagues [33] demonstrated that the continuation of
the use of the so called “d-drugs” such as d4T among pa-
tients who persist with PN from the initial stages did not
show a significant difference between the use of non d-
drugs, in worsening the neuropathy. It is common prac-
tice that in such cases of PN suspected to be as a result
of d4T, the medication is usually discontinued. The ex-
perience of PN at later stages of therapy is likely attrib-
utable to other factors than d4T. On the other hand,
because of the evidence that d4T has been associated
with PN, the medication was reduced and eliminated in
the ARV regimen in some countries (7) including
Rwanda. Thus, few participants were on d4T containing
regimen, of which less number might have statistical
power to demonstrate the significant results.
The duration of HIV infection and duration on ART,
did not independently predict the occurrence of PN after
adjusting for other confounders in a multivariable
model, with exception of the duration of 1 – 3 years that
appeared a predictor of PN. To the authors’ knowledge,
it is not yet clear to why being on ART in the first 3 years
predicts PN than longer periods of 4 – 6 or 7 and above
years. Further investigations into this with longitudinal
study designs would be helpful in clarifying this. Other-
wise, similar findings in other studies in Africa such as
by Oshinaike et al. [12] indicated the trend of ART dur-
ation and non - association with PN. Some other studies
however for instance the one by Robinson-Papp et al
[35], highlighted the duration of HIV infection as a risk
factor for PN. It is important to note that there is likeli-
hood that the duration the patient has been HIV positive
and on ART, may influence the occurrence of PN, but
our study shows that the occurrence is influenced by the
presence of other risk factors, such as duration on ART
particularly during the period of 1 – 3 years on ART. It
is likely the ART associated PN usually manifests during
the first years on the ART [29], and reduces in later
years, probably due to other health care interventions.
However, this could not be confirmed with our cross
sectional study, further studies with longitudinal design
are warranted.
The strength of this study is demonstrated in the large
sample size and inclusion of randomly selected ARTclinics. The use of a more rigorous PN assessment tool
that is considered as a gold standard for the assessment
of HIV – associated PN ensured more reliable data to
determine the prevalence PN in Rwanda. The data in
this study can be used in developing strategies for the
comprehensive management of the condition, particu-
larly among urban and in the older, PLHIV on ART in
Rwanda.
However, the study’s major limitation is that partici-
pants were only outpatients and lacked a balance of pa-
tients at different stages of HIV which might have
influenced the level of CD4 cell count mostly identified
the sample. Additionally, few participants in the sample
were on d4T containing regimen by the time of the
study which may have underestimated the association of
the d4T with PN, tested. Occupational activities were
used to identify the lifestyle of the participants but a
more rigorous assessment procedure to identify the life-
style activities that may be influencing the occurrence of
PN, would strengthen the study. The study is biased
with the cross-sectional study design and with some
retrospective data from the medical file records, whereby
some data such PN prior ART initiation were mostly
missing and the variable could not be included in final
analysis. A cohort study design to assess the factors in-
fluencing the PN among the PLHIV would be essential
to give more evidence. The study also is limited in the
assessment of inter-observer variation between the three
assessors.
Conclusions
The study identified a high prevalence of PN in Rwanda
and this can form the basis for designing strategies for
managing the problem and to prevent or minimise the
effects of PN that compromise the quality of life of
PLHIV. Older PLHIV and living in urban settings, on
ART should have their PN status monitored more so as
to maintain and improve their quality of life appropri-
ately. However, further study into lifestyle behaviour ac-
tivities and other factors that may influence the
occurrence of PN assessed longitudinal design is needed
among PLHIV in urban settings.
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